NICE wants more Abilify data
This article was originally published in Scrip
Executive Summary
NICE, the HTA institute for England and Wales, says that it needs more information from Bristol-Myers Squibb and Otsuka Pharmaceuticals before it can assess whether or not to recommend NHS uptake of Abilify (aripiprazole) for patients aged between 15 and 17 with schizophrenia.